search
Back to results

The Effect of Opioids on P2Y12 Receptor Inhibition in Patients With ST-Elevation Myocardial Infarction Who Are Pre-treated With Crushed Ticagrelor (ON-TIME 3)

Primary Purpose

STEMI, STEMI - ST Elevation Myocardial Infarction

Status
Completed
Phase
Phase 4
Locations
Netherlands
Study Type
Interventional
Intervention
Paracetamol
Fentanyl
Sponsored by
A.H. Tavenier
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for STEMI

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

i. age ≥18 years

ii. referred by ambulance paramedics to Isala (Zwolle) or Zuyderland Hospital (Heerlen)

iii. diagnosed in the ambulance with STEMI defined as:

  1. ongoing chest pain >30 minutes and <12 hours duration and
  2. ST-segment elevation >0.1 milliVolt in at least 2 contiguous leads

iv. ongoing chest pain with a pain score (NRS) ≥4

v. the patient has been informed of the nature of the study, agrees to its provisions and has provided verbal informed consent in the pre-hospital phase followed by written informed consent in hospital

Exclusion Criteria:

i. presenting with cardiogenic shock; defined as:

  1. systolic blood pressure <90 mmHg and
  2. heart rate >100/min and
  3. peripheral oxygen saturation <90% (without oxygen administration)

ii. patients with a nasogastric tube in situ or requiring a nasogastric tube

iii. patients who already received fentanyl or paracetamol <2 hours prior to randomization

iv. patients on current treatment with P2Y12 inhibitors (ticagrelor, clopidogrel or prasugrel)

v. allergy to morphine or paracetamol

vi. patients with recent major bleeding complications or contraindication to dual antiplatelet therapy:

  1. hypersensitivity to aspirin or ticagrelor
  2. current use of (new) oral anticoagulation
  3. history of bleeding diathesis or known coagulopathy
  4. active bleeding
  5. refusal of blood transfusions
  6. history of intracerebral mass, aneurysm, arteriovenous malformation, or hemorrhagic stroke
  7. known severe liver dysfunction

vii. received any organ transplant or is on a waiting list for any organ transplant

viii. patients undergoing dialysis

ix. pregnant or lactating female

x. patients currently participating in another investigational drug or device study

Sites / Locations

  • Isala clinics

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

paracetamol

fentanyl

Arm Description

Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.

Outcomes

Primary Outcome Measures

platelet reactivity
Platelet reactivity units (PRU) directly post-PCI or 1 hour post-angiography

Secondary Outcome Measures

Full Information

First Posted
October 30, 2017
Last Updated
February 11, 2020
Sponsor
A.H. Tavenier
Collaborators
Isala
search

1. Study Identification

Unique Protocol Identification Number
NCT03400267
Brief Title
The Effect of Opioids on P2Y12 Receptor Inhibition in Patients With ST-Elevation Myocardial Infarction Who Are Pre-treated With Crushed Ticagrelor
Acronym
ON-TIME 3
Official Title
The Effect of Opioids on P2Y12 Receptor Inhibition in Patients With ST-Elevation Myocardial Infarction Who Are Pre-treated With Crushed Ticagrelor
Study Type
Interventional

2. Study Status

Record Verification Date
February 2020
Overall Recruitment Status
Completed
Study Start Date
February 16, 2018 (Actual)
Primary Completion Date
October 22, 2019 (Actual)
Study Completion Date
November 22, 2019 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor-Investigator
Name of the Sponsor
A.H. Tavenier
Collaborators
Isala

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
Fast and accurate platelet inhibition is an important therapeutic goal in the acute treatment of patients with ST-segment elevation myocardial infarction (STEMI). Platelet inhibitory effects induced by normal oral P2Y12 receptor antagonists, for example ticagrelor, are delayed in STEMI patients undergoing primary percutaneous coronary intervention (primary PCI), which may be attributed to impaired absorption affecting drug pharmacokinetics (PK) and pharmacodynamics (PD). Another therapeutic goal in the acute treatment of STEMI is reduction of sympathetic stress and catecholamine release, thereby improving the balance between the demand for and supply of oxygen, by analgesia like fentanyl of morphine. To date, there are no studies that have specifically assessed the pharmacodynamics influences of fentanyl on platelet inhibition in STEMI patients who are pre-treated with crushed ticagrelor tablets. Therefore, In the ON-TIME-3 study, the investigators seek to show the influence of fentanyl on platelet inhibition in STEMI patients who are pre-treated with crushed ticagrelor in the ambulance.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
STEMI, STEMI - ST Elevation Myocardial Infarction

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
randomized controlled trial, with randomization to either paracetamol intravenously or fentanyl.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
200 (Actual)

8. Arms, Groups, and Interventions

Arm Title
paracetamol
Arm Type
Active Comparator
Arm Description
Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
Arm Title
fentanyl
Arm Type
Active Comparator
Intervention Type
Drug
Intervention Name(s)
Paracetamol
Intervention Description
Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
Intervention Type
Drug
Intervention Name(s)
Fentanyl
Intervention Description
Patients are randomized to paracetamol 1000 mg iv or fentanyl 1-2 mcg/kg with a maximum of 4 mcg/kg iv.
Primary Outcome Measure Information:
Title
platelet reactivity
Description
Platelet reactivity units (PRU) directly post-PCI or 1 hour post-angiography
Time Frame
directly post-PCI or 1 hour post-angiography

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: i. age ≥18 years ii. referred by ambulance paramedics to Isala (Zwolle) or Zuyderland Hospital (Heerlen) iii. diagnosed in the ambulance with STEMI defined as: ongoing chest pain >30 minutes and <12 hours duration and ST-segment elevation >0.1 milliVolt in at least 2 contiguous leads iv. ongoing chest pain with a pain score (NRS) ≥4 v. the patient has been informed of the nature of the study, agrees to its provisions and has provided verbal informed consent in the pre-hospital phase followed by written informed consent in hospital Exclusion Criteria: i. presenting with cardiogenic shock; defined as: systolic blood pressure <90 mmHg and heart rate >100/min and peripheral oxygen saturation <90% (without oxygen administration) ii. patients with a nasogastric tube in situ or requiring a nasogastric tube iii. patients who already received fentanyl or paracetamol <2 hours prior to randomization iv. patients on current treatment with P2Y12 inhibitors (ticagrelor, clopidogrel or prasugrel) v. allergy to morphine or paracetamol vi. patients with recent major bleeding complications or contraindication to dual antiplatelet therapy: hypersensitivity to aspirin or ticagrelor current use of (new) oral anticoagulation history of bleeding diathesis or known coagulopathy active bleeding refusal of blood transfusions history of intracerebral mass, aneurysm, arteriovenous malformation, or hemorrhagic stroke known severe liver dysfunction vii. received any organ transplant or is on a waiting list for any organ transplant viii. patients undergoing dialysis ix. pregnant or lactating female x. patients currently participating in another investigational drug or device study
Facility Information:
Facility Name
Isala clinics
City
Zwolle
Country
Netherlands

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

The Effect of Opioids on P2Y12 Receptor Inhibition in Patients With ST-Elevation Myocardial Infarction Who Are Pre-treated With Crushed Ticagrelor

We'll reach out to this number within 24 hrs